XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information
 6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Segment Information Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and
drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

The following table presents information about our reportable segments, reconciled to consolidated totals:

 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
($ in millions)
2019
 
2018
 
2019
 
2018
Net sales:
 
 
 
 
 
 
 
Proprietary Products
$
360.3

 
$
346.0

 
$
700.7

 
$
672.2

Contract-Manufactured Products
109.4

 
101.5

 
212.5

 
191.0

Consolidated net sales
$
469.7

 
$
447.5

 
$
913.2

 
$
863.2

Operating profit (loss):
 
 
 
 
 
 
 
Proprietary Products
$
88.8

 
$
71.7

 
$
165.8

 
$
134.5

Contract-Manufactured Products
11.4

 
9.0

 
21.9

 
18.5

Corporate
(18.3
)
 
(18.2
)
 
(34.5
)
 
(33.8
)
Other unallocated items
(1.4
)
 
(2.2
)
 
(2.0
)
 
(5.5
)
Total operating profit
$
80.5

 
$
60.3

 
$
151.2

 
$
113.7

Interest expense
2.0

 
2.2

 
4.3

 
4.1

Interest income
(0.6
)
 
(0.3
)
 
(1.5
)
 
(0.9
)
Other nonoperating income
(0.5
)
 
(1.7
)
 
(1.1
)
 
(3.3
)
Income before income taxes
$
79.6

 
$
60.1

 
$
149.5

 
$
113.8



Other unallocated items during the three and six months ended June 30, 2019 consisted of $1.4 million and $2.0 million, respectively, in restructuring and related charges. Other unallocated items during the three and six months ended June 30, 2018 consisted of $2.2 million and $5.5 million, respectively, in restructuring and related charges. Please refer to Note 15, Other (Income) Expense, for further discussion of these items.